Cargando…
Inhibiting 5‐lipoxygenase prevents skeletal muscle atrophy by targeting organogenesis signalling and insulin‐like growth factor‐1
BACKGROUND: Skeletal muscle atrophy can occur in response to numerous factors, such as ageing and certain medications, and produces a major socio‐economic burden. At present, there are no approved drugs for treating skeletal muscle atrophy. Arachidonate 5‐lipoxygenase (Alox5) is a drug target for a...
Autores principales: | Kim, Hyun‐Jun, Kim, Seon‐Wook, Lee, Sang‐Hoon, Jung, Da‐Woon, Williams, Darren R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745465/ https://www.ncbi.nlm.nih.gov/pubmed/36221153 http://dx.doi.org/10.1002/jcsm.13092 |
Ejemplares similares
-
Investigation of niclosamide as a repurposing agent for skeletal muscle atrophy
por: Kim, Hyun-Jun, et al.
Publicado: (2021) -
Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia
por: Lee, Ji-Hyung, et al.
Publicado: (2021) -
Inhibited inositol monophosphatase and decreased myo‐inositol concentration improve wasting in skeletal muscles
por: Lee, Ji‐Hyung, et al.
Publicado: (2020) -
The BMP Antagonist Follistatin-Like 1 Is Required for Skeletal and Lung Organogenesis
por: Sylva, Marc, et al.
Publicado: (2011) -
Aberrant insulin receptor expression is associated with insulin resistance and skeletal muscle atrophy in myotonic dystrophies
por: Renna, Laura Valentina, et al.
Publicado: (2019)